Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer

被引：0
|
作者：
Yuichi Ozawa
Daisuke Akahori
Keigo Koda
Takefumi Abe
Hirotsugu Hasegawa
Takashi Matsui
Masayuki Tanahashi
Hiroshi Niwa
Kazunari Yamada
Koshi Yokomura
Takafumi Suda
机构：
[1] Seirei Mikatahara General Hospital,Department of Respiratory Medicine, Respiratory Disease Center
[2] Seirei Mikatahara General Hospital,Division of Thoracic Surgery, Respiratory Disease Center
[3] Seirei Mikatahara General Hospital,Department of Radiation Oncology
[4] Hamamatsu University School of Medicine,Second Division, Department of Internal Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 77卷
关键词：
Lung cancer; Interstitial lung disease; Docetaxel; S-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1031 / 1038
页数：7
相关论文
共 50 条
  • [31] Association of pre-existing interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with non-lung cancers
    Shimoji, Kiyofumi
    Masuda, Takeshi
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Iwamoto, Hiroshi
    Fujitaka, Kazunori
    Hamada, Hironobu
    Takeno, Sachio
    Hide, Michihiro
    Teishima, Jun
    Ohdan, Hideki
    Hattori, Noboru
    ANNALS OF ONCOLOGY, 2021, 32 : S302 - S302
  • [32] Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy
    Xiuqiong Chen
    Zhaona Li
    Xinyue Wang
    Jing Zhou
    Qianhui Wei
    Richeng Jiang
    Supportive Care in Cancer, 2022, 30 : 6515 - 6524
  • [33] Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy
    Chen, Xiuqiong
    Li, Zhaona
    Wang, Xinyue
    Zhou, Jing
    Wei, Qianhui
    Jiang, Richeng
    SUPPORTIVE CARE IN CANCER, 2022, 30 (08) : 6515 - 6524
  • [34] IMPACT OF A PRE-EXISTING INTERSTITIAL LUNG DISEASE ON SEVERITY OF COVID-19 IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES
    Juge, P. A.
    Hachulla, E.
    Richez, C.
    Drumez, E.
    Duhamel, A.
    Borie, R.
    Dieude, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 897 - 897
  • [35] Assessing risk factors for COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease
    Huang, Po-Yu
    Lai, Chih-Cheng
    Hsu, Chi-Kuei
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (12)
  • [36] The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer
    Masuda, Takeshi
    Hirano, Chihiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintarou
    Iwamoto, Hiroshi
    Ohshimo, Shinichiro
    Fujitaka, Kazunori
    Hamada, Hironobu
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 131 - 139
  • [37] The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer
    Takeshi Masuda
    Chihiro Hirano
    Yasushi Horimasu
    Taku Nakashima
    Shintarou Miyamoto
    Hiroshi Iwamoto
    Shinichiro Ohshimo
    Kazunori Fujitaka
    Hironobu Hamada
    Noboru Hattori
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 131 - 139
  • [38] Pre-existing diabetes and lung cancer prognosis
    Luo, Juhua
    Hendryx, Michael
    Qi, Lihong
    Ho, Gloria Y. F.
    Margolis, Karen L.
    BRITISH JOURNAL OF CANCER, 2016, 115 (01) : 76 - 79
  • [39] Pre-existing diabetes and lung cancer prognosis
    Juhua Luo
    Michael Hendryx
    Lihong Qi
    Gloria YF Ho
    Karen L Margolis
    British Journal of Cancer, 2016, 115 : 76 - 79
  • [40] Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
    Otani, Toshihito
    Yamaguchi, Kakuhiro
    Nakao, Satoshi
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Miyamoto, Shintaro
    Nakashima, Taku
    Iwamoto, Hiroshi
    Fujitaka, Kazunori
    Hamada, Hironobu
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 857 - 865
12345